Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2022-08-08
DOI
10.1080/17460441.2022.2111415
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repeated low doses of LSD in healthy adults: A placebo‐controlled, dose–response study
- (2022) Harriet Wit et al. ADDICTION BIOLOGY
- Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
- (2022) Natalie Gukasyan et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
- (2022) Jeffrey M. Witkin et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
- (2022) Chia-Ling Yu et al. Journal of Clinical Medicine
- Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
- (2022) Anees Bahji et al. Expert Opinion On Drug Safety
- mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression
- (2022) Lynnette A. Averill et al. JOURNAL OF AFFECTIVE DISORDERS
- The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: A systematic review and updated meta-analysis of double-blind randomized controlled trials
- (2022) Tien-Wei Hsu et al. JOURNAL OF AFFECTIVE DISORDERS
- Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
- (2022) Piotr Popik et al. PSYCHOPHARMACOLOGY
- The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review
- (2022) Andrew Troy Hodge et al. JOURNAL OF PSYCHOACTIVE DRUGS
- Comments to Drs. Bahji, Vazquez, and Zarate
- (2021) Wayne C. Drevets et al. JOURNAL OF AFFECTIVE DISORDERS
- Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
- (2021) Plinio C. Casarotto et al. CELL
- Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
- (2021) Jaclyn N. Highland et al. PHARMACOLOGICAL REVIEWS
- Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
- (2021) Ioline D. Henter et al. CNS DRUGS
- Registered Clinical Studies Investigating Psychedelic Drugs for Psychiatric Disorders
- (2021) Ashley N. Siegel et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
- (2021) Yan Wei et al. MOLECULAR PSYCHIATRY
- Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road
- (2021) Bashkim Kadriu et al. DRUG DISCOVERY TODAY
- Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience
- (2021) Martin K. Madsen et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Evaluation of the safety, tolerability and pharmacokinetic profiles of TP0473292 (TS-161), a prodrug of a novel orthosteric mGlu2/3 receptor antagonist TP0178894, in healthy subjects and its antidepressant-like effects in rodents
- (2021) Mai Watanabe et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals
- (2021) Drummond E-Wen McCulloch et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders
- (2021) Shalini Dogra et al. NEUROPHARMACOLOGY
- BDNF controls GABAAR trafficking and related cognitive processes via autophagic regulation of p62
- (2021) Toshifumi Tomoda et al. NEUROPSYCHOPHARMACOLOGY
- Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
- (2021) Ya-Ting Wang et al. PHARMACOLOGICAL RESEARCH
- The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice
- (2021) Agnieszka Pałucha-Poniewiera et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study
- (2021) Rachel Ochs-Ross et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice
- (2021) Anna Rafało-Ulińska et al. BEHAVIOURAL BRAIN RESEARCH
- Psychedelic medicines for mood disorders: current evidence and clinical considerations
- (2021) Jerome Sarris et al. CURRENT OPINION IN PSYCHIATRY
- The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
- (2021) Gerard Sanacora et al. NATURE REVIEWS NEUROSCIENCE
- GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors
- (2021) Rok Cerne et al. PHARMACOLOGY & THERAPEUTICS
- Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review
- (2021) Nina Schimmel et al. PSYCHOPHARMACOLOGY
- Mechanisms of ketamine and its metabolites as antidepressants
- (2021) Evan M. Hess et al. BIOCHEMICAL PHARMACOLOGY
- Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression
- (2020) Meghan Hibicke et al. ACS Chemical Neuroscience
- ‘That’s the Esketamine, Baby, there’s Nothing You Can Do about It!’ An Update on Glutamatergic System in Suicidal Depression
- (2020) Domenico De Berardis et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Intravenous arketamine for treatment-resistant depression: open-label pilot study
- (2020) Gustavo C. Leal et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects
- (2020) Jeffrey M. Witkin PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- A New Rapid-Acting Antidepressant
- (2020) John H. Krystal et al. CELL
- A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression
- (2020) Lawrence T Park et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
- (2020) Cristan A. Farmer et al. NEUROPSYCHOPHARMACOLOGY
- Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
- (2020) Joanna Kryst et al. Pharmacological Reports
- Cell-type specific modulation of NMDA receptors triggers antidepressant actions
- (2020) Santosh Pothula et al. MOLECULAR PSYCHIATRY
- Distinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats
- (2020) Piotr Popik et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- R-(−)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder1
- (2020) J.M. Witkin et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery
- (2020) Laura Musazzi Expert Opinion on Drug Discovery
- Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
- (2020) Dawn F Ionescu et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
- (2020) Anees Bahji et al. JOURNAL OF AFFECTIVE DISORDERS
- Inhibition of GABA interneurons in the mPFC is sufficient and necessary for rapid antidepressant responses
- (2020) Manoela V. Fogaça et al. MOLECULAR PSYCHIATRY
- Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
- (2020) Bashkim Kadriu et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects
- (2019) Brendan D. Hare et al. Nature Communications
- (2R,6R)-hydroxynorketamine exerts mGlu2receptor-dependent antidepressant actions
- (2019) Panos Zanos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function
- (2019) Eric W. Lumsden et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel pathways in the treatment of Major Depression: focus on the glutamatergic system
- (2019) Carmine Tomasetti et al. CURRENT PHARMACEUTICAL DESIGN
- Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
- (2019) Joanna Kryst et al. EXPERT OPINION ON PHARMACOTHERAPY
- mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects
- (2019) Max E. Joffe et al. NEURON
- Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms
- (2019) Taro Kato et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
- (2019) Satoshi Deyama et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Common Neurotransmission Recruited in ( R , S )-Ketamine and (2 R ,6 R )-Hydroxynorketamine–Induced Sustained Antidepressant-like Effects
- (2018) Thu Ha Pham et al. BIOLOGICAL PSYCHIATRY
- Mechanistic Target of Rapamycin–Independent Antidepressant Effects of ( R )-Ketamine in a Social Defeat Stress Model
- (2018) Chun Yang et al. BIOLOGICAL PSYCHIATRY
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
- (2018) Panos Zanos et al. PHARMACOLOGICAL REVIEWS
- Psychedelics Promote Structural and Functional Neural Plasticity
- (2018) Calvin Ly et al. Cell Reports
- Understanding CNS effects of deliriant hallucinogenic drugs through experimental animal models
- (2018) Andrey D. Volgin et al. ACS Chemical Neuroscience
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
- (2018) Nolan R. Williams et al. AMERICAN JOURNAL OF PSYCHIATRY
- Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
- (2018) Stephanie C. Dulawa et al. MOLECULAR PSYCHIATRY
- The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice
- (2018) Karolina Podkowa et al. NEUROPHARMACOLOGY
- Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders
- (2018) Joanna M. Wierońska et al. PHARMACOLOGY & THERAPEUTICS
- A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
- (2018) Samuel T. Wilkinson et al. DRUG DISCOVERY TODAY
- Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
- (2018) Xenia Gonda et al. Expert Opinion on Drug Discovery
- Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
- (2018) Renee-Marie Ragguett et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- An update on ketamine and its two enantiomers as rapid-acting antidepressants
- (2018) Kai Zhang et al. Expert Review of Neurotherapeutics
- Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen
- (2018) Adam L. Halberstadt et al. PSYCHOPHARMACOLOGY
- The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test
- (2017) Agnieszka Pałucha-Poniewiera et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- mGlu2/3 Receptor Antagonists as Novel Antidepressants
- (2017) Shigeyuki Chaki TRENDS IN PHARMACOLOGICAL SCIENCES
- Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents
- (2017) Cosima Locher et al. JAMA Psychiatry
- The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant
- (2016) Joseph Moskal et al. Current Neuropharmacology
- Clinical applications of hallucinogens: A review.
- (2016) Albert Garcia-Romeu et al. EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
- Ketamine: 50 Years of Modulating the Mind
- (2016) Linda Li et al. Frontiers in Human Neuroscience
- The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
- (2016) RS McIntyre et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine
- (2016) Chao Dong et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- GABA interneurons mediate the rapid antidepressant-like effects of scopolamine
- (2016) Eric S. Wohleb et al. JOURNAL OF CLINICAL INVESTIGATION
- Psychedelics in the treatment of unipolar mood disorders: a systematic review
- (2016) James JH Rucker et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495
- (2016) Karolina Podkowa et al. NEUROPHARMACOLOGY
- Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition
- (2016) Oliver H. Miller et al. NEUROPHARMACOLOGY
- Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats
- (2016) Karolina Podkowa et al. PSYCHOPHARMACOLOGY
- Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
- (2015) Adam L. Halberstadt BEHAVIOURAL BRAIN RESEARCH
- Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors
- (2015) Andrea Navarria et al. NEUROBIOLOGY OF DISEASE
- The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: Central mediators of pathophysiology and antidepressant activity?
- (2015) Florian Freudenberg et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
- (2014) Kyle A.B. Lapidus et al. BIOLOGICAL PSYCHIATRY
- Antidepressant treatment history as a predictor of response to scopolamine: clinical implications
- (2014) Jessica S. Ellis et al. JOURNAL OF AFFECTIVE DISORDERS
- Is the mGlu5 receptor a possible target for new antidepressant drugs?
- (2014) Agnieszka Pałucha-Poniewiera et al. Pharmacological Reports
- Glutamate-Based Antidepressants: Preclinical Psychopharmacology
- (2013) Andrzej Pilc et al. BIOLOGICAL PSYCHIATRY
- Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses
- (2013) Bhavya Voleti et al. BIOLOGICAL PSYCHIATRY
- Scopolamine as an Antidepressant
- (2013) Robert J. Jaffe et al. CLINICAL NEUROPHARMACOLOGY
- CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER
- (2013) Maurizio Fava et al. DEPRESSION AND ANXIETY
- Psilocybin – Summary of knowledge and new perspectives
- (2013) Filip Tylš et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
- (2013) Ji-chun Zhang et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Commentary [The Mood in the Field of Antidepressant Drug Discovery]
- (2012) Jeffrey M. Witkin CNS & Neurological Disorders-Drug Targets
- Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder
- (2012) Danial Khajavi et al. JOURNAL OF CLINICAL PSYCHIATRY
- Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial
- (2012) Kari R Nations et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cost of disorders of the brain in Europe 2010
- (2011) Anders Gustavsson et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The size and burden of mental disorders and other disorders of the brain in Europe 2010
- (2011) H.U. Wittchen et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Presynaptic muscarinic M2 receptors modulate glutamatergic transmission in the bed nucleus of the stria terminalis
- (2011) Ji-Dong Guo et al. NEUROPHARMACOLOGY
- Signaling pathways underlying the rapid antidepressant actions of ketamine
- (2011) Ronald S. Duman et al. NEUROPHARMACOLOGY
- Taming the Ketamine Tiger
- (2010) Edward F. Domino ANESTHESIOLOGY
- Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial
- (2010) Wayne C. Drevets et al. BIOLOGICAL PSYCHIATRY
- Transdermal scopolamine for the prevention of postoperative nausea and vomiting: A systematic review and meta-analysis
- (2010) Christian C. Apfel et al. CLINICAL THERAPEUTICS
- The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
- (2010) Franz X. Vollenweider et al. NATURE REVIEWS NEUROSCIENCE
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
- (2010) N. Li et al. SCIENCE
- Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling
- (2009) K. A. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glutamate-based antidepressants: 20 years on
- (2009) Phil Skolnick et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- AMPA Receptors: A Target for Novel Antidepressants?
- (2008) Phil Skolnick BIOLOGICAL PSYCHIATRY
- What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies
- (2008) Abebaw Fekadu et al. JOURNAL OF AFFECTIVE DISORDERS
- Human hallucinogen research: guidelines for safety
- (2008) MW Johnson et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Identification of a serotonin/glutamate receptor complex implicated in psychosis
- (2008) Javier González-Maeso et al. NATURE
- AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
- (2007) Ce Zhang et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started